March 5 (Reuters) - Johnson & Johnson (NYSE:JNJ) JNJ.N :
* ANTICIPATES FULFILLING 10 MILLION DOSES INCLUDED IN ADVANCE PURCHASE AGREEMENT WITH THE GOVERNMENT OF CANADA BY THE END OF Q3 2021
* PLANS TO FILE FOR A NOTICE OF COMPLIANCE WITH HEALTH CANADA LATER IN 2021
* BEEN WORKING TO DEVELOP AND ACTIVATE MANUFACTURING CAPABILITIES FOR COVID-19 VACCINE, WHICH WILL ENABLE US TO MEET 2021 SUPPLY COMMITMENTS
* COVID-19 VACCINE SHOULD NOT BE RE-FROZEN IF DISTRIBUTED AT TEMPERATURES OF 2°-8°C
* COVID-19 VACCINE ESTIMATED TO REMAIN STABLE FOR 2 YEARS AT -20°C & MAXIMUM OF 3 MONTHS AT ROUTINE REFRIGERATION AT TEMPERATURES OF 2°C TO 8°C